From Quartz.

🎥 Video Details 🎥

🌟 About This Video 🌟
Novo Nordisk sued Hims & Hers over alleged marketing of unapproved weight-loss drug copies, a case with regulatory and patient-safety implications. The complaint says Hims & Hers promoted knockoff versions of Wegovy and Ozempic that bypass FDA review, and Novo seeks a permanent block and damages.
Hims & Hers, which launched a compounded semaglutide pill, said it halted sales Saturday and called the suit an attack on consumer choice. Hims priced month one at $49, about $100 below Novo’s Wegovy pill, recently promoted in a Super Bowl ad with strong demand. The company also cited an FDA warning of possible legal action and acknowledged Novo’s semaglutide patents through 2032. #novonordisk #himsandhers #pharmalawsuit #ozempic #fdawarnings

🤖 Crafted with Rizzle AI 🤖

This video was created using Rizzle AI, the ingenious no-edit video creation platform, with industry-leading assets from GettyImages and Soundstripe. Elevate your video content with Rizzle AI: https://app.rizzle.com/create

🔔 If you enjoyed this video, don’t forget to like, share, and subscribe! 🔔